Get the Stockscreener App
64.59
0.81%
0.52
After Hours:
65.77
1.18
+1.83%
Oruka Therapeutics Inc stock is traded at $64.59, with a volume of 942.41K.
It is up +0.81% in the last 24 hours and up +4.16% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$64.07
Open:
$64.19
24h Volume:
942.41K
Relative Volume:
0.78
Market Cap:
$3.87B
Revenue:
-
Net Income/Loss:
$-105.43M
P/E Ratio:
-27.86
EPS:
-2.3183
Net Cash Flow:
$-88.42M
1W Performance:
+3.21%
1M Performance:
+4.16%
6M Performance:
+132.76%
1Y Performance:
+562.46%
1-Day Range:
$63.68
$65.45
1-Week Range:
$60.98
$71.02
52-Week Range:
$8.91
$91.00
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
64.59 | 3.84B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Psoriasis Data, Halozyme Pact and Equity Raise Might Change The Case For Investing In Oruka Therapeutics (ORKA) - Sahm
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Biotech's 121.89% Potential Upside Captivates Investors - DirectorsTalk Interviews
Halozyme (HALO) Enters Global Partnership with Oruka Therapeutics - GuruFocus
Oruka Therapeutics (ORKA) slides 8.2% as investors digest recent $700M equity raise - Quiver Quantitative
Halozyme and Oruka sign agreement for Hypercon technology - Yahoo Finance
Oruka Therapeutics shares jump on strong psoriasis trial results - MSN
Halozyme Agrees to License Hypercon Technology to Oruka to Develop Psoriasis Treatment - Contract Pharma
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
ORKA stock is soaring after psoriasis trial results — here's why BTIG hiked its price target by 94% - MSN
Halozyme licenses Hypercon technology to Oruka for psoriasis drug By Investing.com - Investing.com Nigeria
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology - PR Newswire
Fairmount funds keep 19.99% Oruka (ORKA) stake under 45-day lock-up - Stock Titan
Assessing Oruka Therapeutics (ORKA) Valuation After Phase 2a Psoriasis Success And Once‑Yearly Dosing Potential - Sahm
Oruka Therapeutics Insider Sold Shares Worth $319,384, According to a Recent SEC Filing - marketscreener.com
ORKA SEC FilingsOruka Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Oruka Therapeutics COO Laura Sandler sells $319,384 in Orka shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Laura Sandler sells $319,384 in Orka shares - Investing.com
Oruka Therapeutics (ORKA) COO sells 5,000 shares and exercises 5,000-share warrant - Stock Titan
Oruka Therapeutics Completes Public Equity Offering Under Shelf - The Globe and Mail
Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Laura Sandler to sell 10,000 ORKA shares (ORKA) via option exercise - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5.9%Here's Why - MarketBeat
Q2 EPS Estimate for Oruka Therapeutics Boosted by Analyst - MarketBeat
Oruka Therapeutics prices upsized $700M public offering at $72.50 per share - MSN
Oruka Therapeutics (ORKA) price target increased by 34.40% to 91.96 - MSN
Oruka Therapeutics (ORKA) sells 9.66M shares at $72.50 in underwritten deal - Stock Titan
Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001 - Yahoo Finance
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Up 22.4% in April - MarketBeat
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque PsoriasisSlideshow (NASDAQ:ORKA) 2026-04-29 - Seeking Alpha
Oruka Therapeutics (ORKA) offers 9.66M shares, raising ~$658M net - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Moody Aldrich Partners LLC Takes $3.84 Million Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
H.C. Wainwright raises Oruka Therapeutics price target to $120 on trial data - Investing.com Canada
Oruka Therapeutics Shares Surpass Record High After Psoriasis Trial - HarianBasis.co
Oruka Therapeutics Prices Upsized $700 Million Share Offering - marketscreener.com
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Oruka Therapeutics prices $700M stock offering at $72.50/share By Investing.com - Investing.com Australia
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Oruka Therapeutics prices $700M stock offering at $72.50/share - Investing.com
Oruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per Share - Quiver Quantitative
Oruka Therapeutics announces pricing of upsized $700 million underwritten public offering - marketscreener.com
Biotech Oruka locks in $700M cash raise at $72.50 a share - Stock Titan
Oruka Therapeutics Announces Pricing Of Upsized $700 Million Underwritten Public Offering - TradingView
Oruka Therapeutics (NASDAQ:ORKA) Trading 6.6% HigherWhat's Next? - MarketBeat
OGN Soars 16.87%, ORKA Hits Record on Healthcare Catalysts - Gotrade
UBS Lifts Price Target on Oruka Therapeutics to $100 From $75, Maintains Buy Rating - marketscreener.com
Oruka reports positive data from Phase IIa trial for plaque psoriasis - Yahoo
Oruka Therapeutics stock hits 52-week high at 90.06 USD By Investing.com - Investing.com South Africa
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering - The Manila Times
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):